Sudarshan Pharma Industries Ltd (SUDARSHAN) — shareholding pattern, promoter holding, financials and share price
About Sudarshan Pharma Industries Ltd (SUDARSHAN)
Sudarshan Pharma Industries Ltd operates in the Specialty Chemicals industry, within the Chemicals sector. It trades on the NSE as SUDARSHAN and on the BSE under scrip code 543828. Its ISIN is INE00TV01023.
Incorporated in 2008, Sudarshan Pharma Industries Ltd manufactures API and Pharmaceutical Items. It also trades in Chemicals and Solvents [1]
Sudarshan Pharma Industries Limited is a vertically integrated pharmaceutical and specialty chemicals company operating across R&D, intermediates, APIs, finished formulations and branded generics, with contract manufacturing, trading subsidiaries and an export-focused footprint spanning Asia, the Middle East, Africa and select Western markets.
Financial momentum is notable: FY25 revenue reached INR 505.0 crore with EBITDA rising 75% to INR 39.9 crore and PAT improving to INR 16.0 crore, reflecting margin expansion driven by increased manufacturing sales, export ramp-up and mix improvement in resale of APIs and intermediates.
Listed peers in Specialty Chemicals: Excel Industries Ltd, Gem Aromatics Ltd, Sunshield Chemicals Ltd, Shri Ahimsa Naturals Ltd, Fairchem Organics Ltd, Indo Amines Ltd.
Valuation & Returns
10 Jul 2026At ₹40 a share on 10 Jul 2026, Sudarshan Pharma Industries Ltd (SUDARSHAN) was valued at a price-to-earnings ratio of 42.73x against an industry P/E of 45.11x and a price-to-book of 7.6x on a book value of ₹5.27 per share as of Mar 2025. Solomo computes return on equity of 17.77% and return on capital employed of 18.61% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 42.73x
- Industry P/E
- 45.11x
- P/B
- 7.6x
- EPS (TTM)
- ₹0.94
- Book value / share
- ₹5.27
- ROE
- 17.77%
- ROCE
- 18.61%
- ROA
- 5.81%
- Debt / equity
- 1.3x
- Dividend yield
- 0%
- EBITDA margin
- 8.54%
- 52-week range
- ₹18.5 – ₹40.9
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Sudarshan Pharma Industries Ltd (SUDARSHAN) reported revenue of ₹703 crore, net profit of ₹23 crore and earnings per share of ₹0.97. That compares with revenue of ₹505 crore and net profit of ₹16 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹221 crore and net profit ₹11 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 357 | 461 | 464 | 505 | 703 |
| Net profit (₹ cr) | 5 | 7 | 11 | 16 | 23 |
| EPS (₹) | 0.54 | 0.29 | 0.48 | 0.66 | 0.97 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 27.70% | 12.06% | 8.96% |
| Profit growth | 65.59% | 44.59% | 39.18% |
| Stock price CAGR | - | 86% | 38% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 58.93% of Sudarshan Pharma Industries Ltd (SUDARSHAN) (up 1.54 pp QoQ), foreign institutional investors (FII) hold 19.38%. Promoters have pledged 1.4% of their holding. Market capitalisation was ₹999 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2023.
Largest disclosed public shareholders in Jun 2026: MULTITUDE GROWTH FUNDS LIMITED 4.68%, CENTURY INDIA OPPORTUNITY FUND PC 3.24%, EMINENCE GLOBAL FUND PCC- EUBILIA CAPITAL PARTNERS 1.95%, EBISU GLOBAL OPPORTUNITIES FUND LIMITED 1.92%, NEXPACT LIMITED 1.83%, COEUS GLOBAL OPPORTUNITIES FUND 1.68%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 58.93% | 1.4% | 19.38% | - | 41.07% |
| Mar 2026 | 57.39% | - | 19.95% | - | 42.61% |
| Dec 2025 | 57.39% | - | 19.78% | - | 42.61% |
| Sep 2025 | 57.39% | - | 20.79% | - | 42.61% |
| Jun 2025 | 57.39% | - | 19.48% | - | 42.61% |
| Mar 2025 | 57.39% | - | 18.45% | - | 42.61% |
| Sep 2024 | 57.39% | - | 13.07% | - | 42.61% |
| Mar 2024 | 57.39% | - | 1.4% | - | 42.61% |